advanced search

PREFILLED SYRINGES

SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?
SUSTAINABILITY
Fran Pencliffe
Cambridge Design Partnership
SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?
Fran Penrose considers the lessons the healthcare sector can draw from the fast-moving consumer sector when designing for sustainability and asks, “Can we go even further?”
SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT
SUSTAINABILITY
Rob Doorakkers
IGS GeboJagema
SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT
Rob Doorakkers and Geert van Amstel discuss why the company decided to become carbon neutral, how it is working to make injection moulding more sustainable and how the organisation is minimising its impact on the environment.
DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS
SUSTAINABILITY
Dr Pierre Moulinie
Covestro LLC
DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS
Pierre Moulinié, Isaac Platte and Lauren Zetts discuss how polycarbonate-based materials deliver value to emerging drug delivery devices.
SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: THE ROUTE TO FURTHER IMPROVEMENTS
SUSTAINABILITY
Emil Fraenkel
Phillips Medisize
SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: THE ROUTE TO FURTHER IMPROVEMENTS
Emil Fraenkel and Bjarne Sørensen investigate the route to further sustainability improvements for the Aria autoinjector. This article is a sequel to a benchmark study on the environmental impact of Aria presented by Phillips-Medisize in ONdrugDelivery Issue 126 (Oct/Nov 2021).
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
OCULAR
Dr Andrea Allmendinger
ten23 health
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.
OPHTHALMIC INJECTION OF VISCOUS FORMULATIONS – WHY UNIQUE NEEDS REQUIRE A NOVEL DELIVERY APPROACH
OCULAR
Dr Gautam Shetty
Congruence Medical Solutions
OPHTHALMIC INJECTION OF VISCOUS FORMULATIONS – WHY UNIQUE NEEDS REQUIRE A NOVEL DELIVERY APPROACH
Guatam Shetty and Richard Whelton outline the key considerations related to ophthalmic injection of viscous formulations and propose an innovative, user-validated and fully mechanical device-based solution.
A VIEW ON THE USE OF APROTIC SOLVENTS IN PARENTERAL DRUG FORMULATIONS
EXPERT VIEW
Michael Neely
A VIEW ON THE USE OF APROTIC SOLVENTS IN PARENTERAL DRUG FORMULATIONS
Michael Neely presents a review and discussion of the status of aprotic solvents as a solubilising vehicle for parenteral drug formulations in the context of the industry’s increasing interest in biologic drugs.
HOW MODEL BASED DEFINITION REVOLUTIONISES THE PRODUCTION OF MEDICAL DEVICES
INDUSTRIALISATION
Rob Doorakkers
IGS GeboJagema
HOW MODEL BASED DEFINITION REVOLUTIONISES THE PRODUCTION OF MEDICAL DEVICES
Rob Doorakkers looks at the advantages of the IGS GeboJagema’s Model Based Definition process and its ability to improve the quality of medical device production.
COMPUTATIONAL MODELLING OF INJECTION-RELATED TISSUE RESPONSES IN DRUG DELIVERY
INJECTION
Asmita Khanolkar
SMC Ltd
COMPUTATIONAL MODELLING OF INJECTION-RELATED TISSUE RESPONSES IN DRUG DELIVERY
Olivia Jefferies, Elizabeth Margerison and Asmita Khanolkar introduce Oval’s work on using ultrasound scanning and finite element analysis to construct a model of how tissue compresses under use of an autoinjector across patient demographics, and how this may provide insights into improved autoinjector design for more accurate injection depths, improving patient outcomes.
DRUG DELIVERY DEVICE TRENDS FOR 2022
EXPERT VIEW
Tom Oakley
DRUG DELIVERY DEVICE TRENDS FOR 2022
Tom Oakley looks at some of the current trends in the drug delivery industry and projects some of the key factors that will influence drug delivery decision making in 2022.
SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES
SUSTAINABILITY
Michael Earl
Owen Mumford
SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES
Michael Earl discusses the highlights of a review undertaken by Owen Mumford into how the pharmaceutical industry is faring on environmental, social and governance standards, noting that while the industry is performing above average overall, there remain some key areas for improvement.
MDR COMPLIANCE: PLANNING FOR POST-MARKET CLINICAL FOLLOW-UP
EXPERT VIEW
Dr Celeste Maksim
MDR COMPLIANCE: PLANNING FOR POST-MARKET CLINICAL FOLLOW-UP
Celeste Maksim discusses best practices for drug delivery device manufacturers when conducting post-market clinical follow-up activities, as mandated by the EU Medical Device Regulation.
TAKING INTEGRATED NEEDLE SAFETY SYSTEMS FOR PREFILLED SYRINGES TO THE NEXT LEVEL
PREFILLED SYRINGES
Michelle Deutsch
SCHOTT Pharma
TAKING INTEGRATED NEEDLE SAFETY SYSTEMS FOR PREFILLED SYRINGES TO THE NEXT LEVEL
Michelle Deutsch and John Merhige discuss the needle safety requirements of prefilled syringes and consider how SCHOTT TOPPAC® and syriQ® PFS with Credence Companion® technology combine to meet these challenges, while ensuring the device meets sustainability demands.
NEW BD SCF™ PREMIUMCOAT<sup>®</sup> 1MLL PLUNGER STOPPER: GLIDING TOWARDS DE-RISKED COMBINATION PRODUCT DEVELOPMENT
PREFILLED SYRINGES
Victoria Meyer
BD (Becton Dickinson & Company)
NEW BD SCF™ PREMIUMCOAT® 1MLL PLUNGER STOPPER: GLIDING TOWARDS DE-RISKED COMBINATION PRODUCT DEVELOPMENT
Victoria Meyer introduces the BD SCF™ PremiumCoat® 1mlL Plunger Stopper and explains how the product’s role is critical in determining combination products’ exposure to extractables and leachables.
FROM VIAL TO PREFILLED SYRINGE: MIGRATING A DRUG PRODUCT PRESENTATION
PREFILLED SYRINGES
Dr Martin Gonzalez
Pfizer CentreOne
FROM VIAL TO PREFILLED SYRINGE: MIGRATING A DRUG PRODUCT PRESENTATION
Martin Gonzalez discusses some of the most relevant engineering activities that are necessary to transfer a product successfully from a vial into a prefilled syringe presentation.
PHOTO-STABILITY TESTS OF EPINEPHRINE
PREFILLED SYRINGES
Yoshiko Sakuma
Mitsubishi Gas Chemical
PHOTO-STABILITY TESTS OF EPINEPHRINE
Yoshiko Sakuma and Tomohiro Suzuki provide an overview of OXYCAPT multilayer vial and syringe, with a particular emphasis on the advantages of OXYCAPT as a container for adrenaline, as demonstrated by recent studies conducted by MGC.
Interview: Arnaud Guillet, Biocorp
INTERVIEW
Arnaud Guillet
Biocorp
Interview: Arnaud Guillet, Biocorp
In this exclusive interview with ONdrugDelivery, Arnaud Guillet discusses Mallya, Biocorp’s connected clip-on for pen injectors, including Mallya’s successful launch in multiple countries this year, the factors that have played into the device’s success, and the future for Mallya, Biocorp and connectivity in the drug delivery industry.
YPSOMATE ON – GO FOR SIMPLY CONNECTED
CONNECTIVITY
Philippe Müller
Ypsomed
YPSOMATE ON – GO FOR SIMPLY CONNECTED
Philippe Müller and Silas Mächler discuss the benefits of integrated digital therapy management systems and the role of YpsoMate On –  the newest addition to Ypsomed’s connected device portfolio, and the world’s first prefilled autoinjector with integrated connectivity that automatically logs injections on the user’s therapy management app.
TRIALS WITHOUT TRIBULATIONS: A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED AND HYBRID CLINICAL TRIALS
CONNECTIVITY
Rebecca Beck
BD (Becton Dickinson & Company)
TRIALS WITHOUT TRIBULATIONS: A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED AND HYBRID CLINICAL TRIALS
Rebecca Beck and Hervé Monchoix discuss how stakeholder needs are driving the development of a new, connected injection device from BD, to support decentralised and hybrid clinical trials.
ROUNDTABLE: ALLIANCE TO ZERO
ROUNDTABLE
Sebastian Gerner
Alliance to Zero
ROUNDTABLE: ALLIANCE TO ZERO
Sebastian Gerner, Robert O’Beirn and Sabrina Gérard talk with ONdrugDelivery about the Alliance to Zero, an association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net-zero emissions.
STRATEGIES TO ACHIEVE LONG-TERM SUSTAINABILITY
SUSTAINABILITY
Peter Soelkner
Vetter Pharma
STRATEGIES TO ACHIEVE LONG-TERM SUSTAINABILITY
Peter Soelkner and Thomas Otto discuss how the pharmaceutical service provider focuses on sustainability.
SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: A LIFECYCLE ASSESSMENT
SUSTAINABILITY
Emil Fraenkel
Phillips Medisize
SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: A LIFECYCLE ASSESSMENT
Emil Fraenkel and Bjarne Sørensen consider the sustainability of re-usable and disposable autoinjectors, its implications in adding connectivity to drug delivery devices and how it has been an important consideration for Phillips-Medisize in the development of the Aria re-usable autoinjector. 
FORMULATION DEVELOPMENT AND DRUG DELIVERY: JOINED AT THE DEVICE
SUSTAINABILITY
Julie Cotterell
Owen Mumford
FORMULATION DEVELOPMENT AND DRUG DELIVERY: JOINED AT THE DEVICE
Julie Cotterell discusses the major factors at play driving the direction of innovation in the subcutaneous drug delivery space, with a particular emphasis on the push towards patient self-administration.
CREATING TIMELESS DEVICE TECHNOLOGIES
INJECTION
Andrew Moore
SHL Medical
CREATING TIMELESS DEVICE TECHNOLOGIES
Andrew Moore and Gene Rhode Fuensalida Pantig discuss the importance of a sound strategy for product lifecycle management.
Top